SE9702457D0 - Screening - Google Patents

Screening

Info

Publication number
SE9702457D0
SE9702457D0 SE9702457A SE9702457A SE9702457D0 SE 9702457 D0 SE9702457 D0 SE 9702457D0 SE 9702457 A SE9702457 A SE 9702457A SE 9702457 A SE9702457 A SE 9702457A SE 9702457 D0 SE9702457 D0 SE 9702457D0
Authority
SE
Sweden
Prior art keywords
diabetes mellitus
metabolic syndrome
dependent diabetes
insulin dependent
obesity
Prior art date
Application number
SE9702457A
Other languages
English (en)
Swedish (sv)
Inventor
Peter Lind
Erik Walum
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9702457A priority Critical patent/SE9702457D0/xx
Publication of SE9702457D0 publication Critical patent/SE9702457D0/xx
Priority to CA002295747A priority patent/CA2295747A1/en
Priority to DE69809558T priority patent/DE69809558T2/de
Priority to PCT/SE1998/001232 priority patent/WO1999000123A1/en
Priority to AU79513/98A priority patent/AU744134B2/en
Priority to AT98930032T priority patent/ATE227986T1/de
Priority to NZ502112A priority patent/NZ502112A/en
Priority to EP98930032A priority patent/EP1001758B1/en
Priority to JP50549299A priority patent/JP2002508770A/ja
Priority to US09/105,035 priority patent/US6001578A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
SE9702457A 1997-06-26 1997-06-26 Screening SE9702457D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9702457A SE9702457D0 (sv) 1997-06-26 1997-06-26 Screening
CA002295747A CA2295747A1 (en) 1997-06-26 1998-06-24 Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity
DE69809558T DE69809558T2 (de) 1997-06-26 1998-06-24 Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2
PCT/SE1998/001232 WO1999000123A1 (en) 1997-06-26 1998-06-24 Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity
AU79513/98A AU744134B2 (en) 1997-06-26 1998-06-24 Use of a drug capable of modulating the regulation of UPC-2 and method for screening for potential drugs against obesity
AT98930032T ATE227986T1 (de) 1997-06-26 1998-06-24 Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2
NZ502112A NZ502112A (en) 1997-06-26 1998-06-24 Method for treating obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus
EP98930032A EP1001758B1 (en) 1997-06-26 1998-06-24 Method of screening of potential drugs against obesity, capable of modulating the regulation of ucp-2
JP50549299A JP2002508770A (ja) 1997-06-26 1998-06-24 Ｕｃｐ−２の調節を変化させることが可能な薬剤の使用および肥満に対抗する可能性のある薬剤のスクリーニング方法
US09/105,035 US6001578A (en) 1997-06-26 1998-06-26 Methods of screening for modulators of uncoupling protein-2 (UCP-2) as potential treatments for obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702457A SE9702457D0 (sv) 1997-06-26 1997-06-26 Screening

Publications (1)

Publication Number Publication Date
SE9702457D0 true SE9702457D0 (sv) 1997-06-26

Family

ID=20407529

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702457A SE9702457D0 (sv) 1997-06-26 1997-06-26 Screening

Country Status (9)

Country Link
EP (1) EP1001758B1 (xx)
JP (1) JP2002508770A (xx)
AT (1) ATE227986T1 (xx)
AU (1) AU744134B2 (xx)
CA (1) CA2295747A1 (xx)
DE (1) DE69809558T2 (xx)
NZ (1) NZ502112A (xx)
SE (1) SE9702457D0 (xx)
WO (1) WO1999000123A1 (xx)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023568A2 (en) * 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
WO2001035096A2 (en) * 1999-11-10 2001-05-17 Mitokor Diseases associated with altered mitochondrial function
US6365796B1 (en) * 2000-02-16 2002-04-02 Beth Israel Deaconess Medical Center Transgenic UCP2 knockout mouse and use thereof
EP1294877B1 (en) 2000-06-22 2005-09-21 Genentech, Inc. Cgi-69 compositions and methods of use
ES2177404B1 (es) * 2000-07-07 2004-09-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la determinacion de la actividad de las proteinas desacoplantes (ucps) mediante la monitorizacion del consumo de nad (p) h.
WO2003002732A1 (en) * 2001-06-27 2003-01-09 Biovitrum Ab Citrate lyase poly peptides
WO2003061681A2 (en) * 2002-01-25 2003-07-31 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis and organelle metabolism
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
FR2853911B1 (fr) * 2003-04-17 2005-07-08 Merck Sante Sas Gene induit par l'insuline, comme cible therapeutique dans le diabete
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
EP1717313A4 (en) * 2003-09-22 2007-11-14 Univ Kyoto NUCLEIC ACID PROBE, NUCLEIC ACID CHIP, METHOD FOR DETECTION OF TARGET NUCLEIC ACID, METHOD FOR DETECTING MEDICINE, APPARATUS FOR DETECTING TARGET NUCLEIC ACID, AND GENE DIAGNOSTIC METHOD
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
CA2577060A1 (en) 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
ES2574014T3 (es) 2005-05-30 2016-06-14 Msd K.K. Derivado de piperidina novedoso
EP1916239A4 (en) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd PYRIDONE COMPOUND
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
BRPI0617621A2 (pt) 2005-10-21 2011-08-02 Novartis Ag combinação de compostos orgánicos
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
MY146564A (en) 2005-11-10 2012-08-30 Msd Kk Aza-substituted spiro derivatives
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (fr) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. dÉrivÉ de diarylcÉtimine
JP4814774B2 (ja) 2006-12-06 2011-11-16 花王株式会社 肥満調節剤の評価方法
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009069546A1 (ja) * 2007-11-26 2009-06-04 Japan Science And Technology Agency 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6769963B2 (ja) 2014-08-29 2020-10-14 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623619A (en) * 1982-03-03 1986-11-18 Nordisk Insulinlaboratorium Method for the determination of liability in human individuals to develop atherosclerosis
FR2557137B1 (fr) * 1983-12-21 1986-05-23 Centre Nat Rech Scient Sonde d'adnc reconnaissant l'arnm de la proteine decouplante des mitochondries du tissu adipeux brun des mammiferes, procede de preparation et application
PT793646E (pt) * 1994-11-23 2002-03-28 Biovitrum Ab Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente
FR2733513B1 (fr) * 1995-04-25 1997-07-18 Centre Nat Rech Scient Lignees immortalisees de cellules issues du tissu adipeux humain, leur procede de preparation et leurs applications
US5783408A (en) * 1995-06-07 1998-07-21 Hamilton; Bradford S. Method for screening potential anti-obesity agents
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
WO1998031396A1 (en) * 1997-01-15 1998-07-23 Duke University Respiration uncoupling protein

Also Published As

Publication number Publication date
ATE227986T1 (de) 2002-12-15
DE69809558T2 (de) 2003-04-10
AU744134B2 (en) 2002-02-14
CA2295747A1 (en) 1999-01-07
EP1001758B1 (en) 2002-11-20
JP2002508770A (ja) 2002-03-19
EP1001758A1 (en) 2000-05-24
WO1999000123A1 (en) 1999-01-07
AU7951398A (en) 1999-01-19
DE69809558D1 (de) 2003-01-02
NZ502112A (en) 2002-02-01

Similar Documents

Publication Publication Date Title
SE9702457D0 (sv) Screening
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
BR0210167A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
BR9906796A (pt) Método para a administração de análogos de insulina monoméricos
EA200400589A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
IL208184A0 (en) Glp-1, and methods for treating diabetes
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
BR0014679A (pt) 2-tio-3,5-diciano-4-aril-6-aminopiridinas substituìdas e sua aplicação
BRPI0512756A (pt) composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
ITRM990338A0 (it) Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
WO2003034803A3 (en) Methods for determining toxicity reversing agents
MX9400287A (es) Procedimiento para la preparacion de un medicamento util para el tratamiento de la enfermedad de parkinson
HUP0402506A2 (hu) FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
BR0011928A (pt) Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética
DE69717301D1 (de) Verwendung von wachstumshormone
ATE199829T1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
BRPI0407421A (pt) Terapia combinada para o tratamento de distúrbios imunoinflamatórios